Harvard Bioscience, Inc.
HBIO
$0.7754
$0.00150.19%
| Weiss Ratings | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.15 | |||
| Price History | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -8.07% | |||
| 30-Day Total Return | -56.92% | |||
| 60-Day Total Return | -66.86% | |||
| 90-Day Total Return | -67.96% | |||
| Year to Date Total Return | -61.80% | |||
| 1-Year Total Return | -82.22% | |||
| 2-Year Total Return | -69.71% | |||
| 3-Year Total Return | -87.51% | |||
| 5-Year Total Return | -68.61% | |||
| 52-Week High % Change | -83.53% | |||
| 52-Week Low % Change | 0.51% | |||
| Price | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.70 | |||
| 52-Week Low Price | $0.77 | |||
| 52-Week Low Price (Date) | Mar 10, 2025 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 33.75M | |||
| Enterprise Value | 75.10M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.33 | |||
| Earnings Per Share Growth | 302.30% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.35 | |||
| Price/Book (Q) | 0.52 | |||
| Enterprise Value/Revenue (TTM) | 0.77 | |||
| Price | $0.78 | |||
| Enterprise Value/EBITDA (TTM) | 31.16 | |||
| Enterprise Value/EBIT | -15.76 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 43.61M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 508 893 8999 | |||
| Address | 84 October Hill Road Holliston, MA 01746 | |||
| Website | www.harvardbioscience.com | |||
| Country | United States | |||
| Year Founded | 1901 | |||
| Profitability | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -4.87% | |||
| Profit Margin | -14.57% | |||
| Management Effectiveness | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -2.20% | |||
| Return on Equity | -- | |||
| Income Statement | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 97.73M | |||
| Total Revenue (TTM) | 97.73M | |||
| Revenue Per Share | $2.24 | |||
| Gross Profit (TTM) | 57.40M | |||
| EBITDA (TTM) | 2.41M | |||
| EBIT (TTM) | -4.76M | |||
| Net Income (TTM) | -14.24M | |||
| Net Income Avl. to Common (TTM) | -14.24M | |||
| Total Revenue Growth (Q YOY) | -13.38% | |||
| Earnings Growth (Q YOY) | -287.57% | |||
| EPS Diluted (TTM) | -0.33 | |||
| EPS Diluted Growth (Q YOY) | -267.00% | |||
| Balance Sheet | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 4.57M | |||
| Cash Per Share (Q) | $0.10 | |||
| Total Current Assets (Q) | 46.79M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 65.32M | |||
| Current Ratio (Q) | 2.057 | |||
| Book Value Per Share (Q) | $1.50 | |||
| Total Assets (Q) | 131.24M | |||
| Total Current Liabilities (Q) | 22.75M | |||
| Total Debt (Q) | 45.91M | |||
| Total Liabilities (Q) | 65.92M | |||
| Total Common Equity (Q) | 65.32M | |||
| Cash Flow | HBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.94M | |||
| Cash from Financing (TTM) | -2.89M | |||
| Net Change in Cash (TTM) | -771.00K | |||
| Levered Free Cash Flow (TTM) | 5.76M | |||
| Cash from Operations (TTM) | 4.02M | |||
